According to the Complaint, ACELYRIN, Inc. is a clinical biopharma company that focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with purportedly high potency, which is presently in Part B of Phase 2b/3 clinical trials for use in the treatment of moderate to severe Hidradenitis Suppurativa ("HS").

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) izokibep was less effective in treating HS than Defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects; (iii) as a result, Acelyrin also overstated the Company's business prospects post-IPO; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

On February 14, 2023, the Court issued an Order appointing Co-Lead Plaintiffs and Counsel. Co-Lead Plaintiffs filed an amended Complaint on March 26, 2024. Defendants filed a Motion to Dismiss the amended Complaint on May 3.

On October 7, 2024, the Court issued an in chambers Order denying Defendants' Motion to Dismiss.